Article Text

AB0007 The CD226 gene is not involved in giant cell arteritis in the spanish caucasian population
  1. A. Serrano1,
  2. D. Carmona1,
  3. J.A. Miranda-Filloy2,
  4. S. Castañeda3,
  5. L. Rodríguez-Rodríguez4,
  6. I. Morado4,
  7. C. Gόmez-Vaquero5,
  8. R. Solans6,
  9. B. Sopeña7,
  10. R. Blanco8,
  11. A. Unzurrunzaga9,
  12. N. Ortego-Centeno10,
  13. B. Marí-Alfonso11,
  14. E. de Miguel12,
  15. A. Hidalgo-Conde13,
  16. J. Martín14,
  17. M.A. González-Gay15
  1. 1Genetics, Institute of Parasitology and Biomedicine “Lόpez-Neyra”, Granada
  2. 2Rheumatology, Hospital Xeral-Calde, Lugo
  3. 3Rheumatology, Hospital de la Princesa, IIS-Princesa
  4. 4Rheumatology, Hospital Clínico San Carlos., Madrid
  5. 5Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona
  6. 6Internal Medicine, Hospital Vall d’Hebron, Barcelona
  7. 7Thrombosis and Vasculitis Unit-Internal Medicine, Thrombosis and Vasculitis Unit-Internal Medicine Department, Complejo Hospitalario Universitario de Vigo, Spain, Vigo
  8. 8Rheumatology, Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Ifimav., Santander
  9. 9Internal Medicine, Hospital de Galdakano, Vizcaya
  10. 10Internal Medicine, Hospital Clínico Universitario San Cecilio, Granada
  11. 11Internal Medicine, Instituto Universitario Parc Taulí, UAB, Sabadell, Barcelona
  12. 12Rheumatology, Hospital Universitario de La Paz, Madrid
  13. 13Internal Medicine, Hospital Universitario Virgen de la Victoria, Málaga
  14. 14Genetics, Instituto de Parasitología y Biomedicina Lόpez-Neyra, CSIC, Granada
  15. 15Rheumatology, Hospital Universitario Marqués de Valdecilla, Ifimav., Santander, Spain


Background CD226 genetic variants have been associated with a number of autoimmune diseases.

Objectives The aim of this study was to investigate the potential implication of the CD226 loci in the susceptibility to and main clinical manifestations of giant cell arteritis (GCA).

Methods A Spanish Caucasian cohort of 455 patients diagnosed with biopsy-proven

GCA and 1414 healthy controls were included in the study. Three CD226 polymorphisms, rs727088, rs34794968 and rs763361, were genotyped using the TaqMan® allelic discrimination technology. PLINK software was used for the statistical analyses.

Results No significant association between the CD226 polymorphisms and susceptibility to GCA was found (rs727088: P=0.92, OR=1.01 CI 95% 0.86-1.18; rs34794968: P=0.61, OR=1.04 CI 95% 0.89-1.22; rs763361: P=0.88, OR=0.99 CI 95% 0.84-1.16). Similarly, when patients were stratified according to the specific clinical features of GCA such as polymyalgia rheumatica, visual ischemic manifestations or irreversible occlusive disease, no association was observed either between the case subgroups and the control set or between GCA patients with and without the specific features of the disease. Furthermore, the haplotype analysis revealed no significant association with the disease.

Conclusions Our results show that the CD226 gene does not play a relevant role in the susceptibility to GCA and clinical manifestations of this vasculitis.

  1. Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009; 10:5-10.

  2. Lofgren SE, Delgado-Vega AM, Gallant CJ, Sanchez E, Frostegard J, Truedsson L, et al. A 3’-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2010; 62:3404-3414.

  3. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002; 347:261-271.

  4. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009; 61:1454-1461.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.